6 completed, 4 terminated. 6 Phase 2, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Terminated 3 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Not applicable | 1 | Completed 1 |
Follow Stage IB Non-Small Cell Lung Carcinoma: new trials by email Literature Review of Stage IB Non-Small Cell Lung Carcinoma trials Research Report on Stage IB Non-Small Cell Lung Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer Nivolumab, Cisplatin, Pemetrexed Disodium - Non-Squamous Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 14 | 2017-12-20 | 2026-02-20 |
| Dynamic Perfusion Computed Tomography in Patients With Localized Non-small Cell Lung Cancer Computed Tomography Perfusion Imaging, Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy - Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma | Completed | University of Southern California | 15 | 2017-05-08 | 2024-07-11 | |
| S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) Preventive Intervention, Quality-of-Life Assessment, Questionnaire Administration - Febrile Neutropenia, Stage 0 Breast Cancer | Not applicable | Completed | SWOG Cancer Research Network | 3665 | 2016-10-07 | 2022-10-20 |
| SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer Fresolimumab, Stereotactic Body Radiation Therapy - Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Completed | Maximilian Diehn | 28 | 2016-08-01 | 2024-03-27 |
| Clinicopathological Characteristics and Prognosis Analysis of Stage IB Non-small Cell Lung Cancer Stage IB Non-Small Cell Lung Carcinoma | Completed | Shanghai Zhongshan Hospital | 971 | 2016-01-01 | 2023-08-07 | |
| Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery Azacitidine, Entinostat, Laboratory Biomarker Analysis - Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 40 | 2013-06-01 | 2016-11-18 |
| Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung Cancer Laboratory Biomarker Analysis, Pioglitazone Hydrochloride, Quality-of-Life Assessment - Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 6 | 2011-04-01 | 2017-12-05 |
| Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery Azacitidine, Entinostat, Laboratory Biomarker Analysis - Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 13 | 2010-09-01 | 2019-02-05 |
| A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC Cisplatin, CT, Docetaxel - Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 26 | 2009-09-01 | 2017-03-17 |
| EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer EF5, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery - Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 28 | 2002-05-01 | 2015-04-13 |
Carcinoma, Non-Small-Cell Lung (10) · Breast Carcinoma In Situ (1) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Febrile Neutropenia (1)
Bronchial Neoplasms (10) · Carcinoma, Bronchogenic (10) · Lung Diseases (10) · Lung Neoplasms (10) · Neoplasms (10) · Neoplasms by Site (10) · Respiratory Tract Diseases (10) · Respiratory Tract Neoplasms (10) · Thoracic Neoplasms (10) · Agranulocytosis (1) · Breast Diseases (1) · Carcinoma (1) · Carcinoma in Situ (1) · Colonic Diseases (1) · Cytopenia (1)
1,2-diaminocyclohexaneplatinum II citrate (2) · Azacitidine (2) · Cisplatin (2) · Radiosurgery (2) · entinostat (2) · Disulfides (1) · Docetaxel (1) · Fluorodeoxyglucose F18 (1) · Gemcitabine (1) · Immunoglobulin G (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Pemetrexed (1) · Pioglitazone (1) · Platinum (1)
National Cancer Institute (NCI) (5) · Maximilian Diehn (1) · SWOG Cancer Research Network (1) · Shanghai Zhongshan Hospital (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Southern California (1)
United States (9) · China (1) · Puerto Rico (1)
Charles Rudin (1) · Christopher Lee, MD (1) · Di Ge, Ph.D;M.D (1) · Maximilian Diehn (1) · Michael Kelley (1) · Montaser Shaheen (1) · Paul Limburg (1) · Richard Wahl (1) · Rita Axelrod, MD (1) · Scott Ramsey (1)
PMID 35365139, PMID 36228177, PMID 36279134, PMID 37770704, PMID 37788414
P30CA006973 (2), N01CM00070 (1), N01CN00042 (1), N01CN35000 (1), P30CA014089 (1), P30CA014236 (1), P30CA015083 (1), P30CA118100 (1), R21CA091565 (1), R21CA161561 (1), UG1CA189974 (1)